2014年10月28日星期二

[醫學]Crohn Disease (慢性腸炎,又稱為克羅恩氏病)

翻譯自JAMA期刊:
JAMA Patient Page: Crohn Disease
患有克羅恩氏病的患者,其表現為消化道的組織有炎症現象。
克羅恩氏病是慢性腸組織炎症的一種(IBD)。表現為慢性病程(病程持久),一般有家族史,可以在任何年齡迅速進展,但主要在20-30歲患者多見。

2014年8月21日星期四

【醫學資源】健檢項目及意義

找到一篇資源,晨星網路書局出版,由詹啟豪博士著作的健檢報告完全手冊,希望能夠幫助民眾能更快速有效了解健康檢查的項目及意義。

下載鏈接:
http://booklook.morningstar.com.tw/pdf/0139022.pdf

2014年8月5日星期二

[ 醫學資訊 ]Information form Morphosys

MOR202 for MM

Is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma (MM) and certain leukemias. In preclinical studies MOR202 mediated antibody-dependent cell-mediated cytotoxicity in MM cells derived from patients in vitro.  Either Velcade® (bortezomib) or Revlimid® (lenalidomide) enhanced the cytotoxic activity of MOR202 in vitro and also the inhibition of MM-mediated bone lysis and tumor load in vivo. The enhancement by bortezomib was mediated through a direct cytotoxic effect on MM cells.

Lenalidomide synergistically enhanced MOR202 activity by several mechanisms identified to be direct cytotoxicity, activation of effector cells and increased CD38 expression levels on MM cells. In an orthotopic xenograft murine model of multiple myeloma, MOR202 reduced tumor load and tumor mediated bone lysis. Co-administration of MOR202 with either bortezomib or lenalidomide completely abolished bone lysis in a synergistic manner. These findings support further investigation of MOR202 combination regimens in clinical trials.

MOR202 is currently being tested in a phase 1/2a trial* in patients with relapsed/refractory myeloma. MOR202 is part of MorphoSys's collaboration with Celgene.

2014年5月21日星期三

140521 我和鋼筆那些事

關於我和鋼筆那些事



最近看到鋼筆終於重新進入年輕一代的視線,覺得十分開心,有時候經典才是永恆,就像email充斥的時代,大家開始懷念信件給人的感動…

從什麽時候有第一隻鋼筆,我不記得了,印象中是老爸那隻退伍不知道幾週年發的一直Parker筆,小時候因為太重,所以從來沒用過。有自己的第一隻鋼筆,就是彎尖鋼筆,拿來心血來潮練字用。

真正和鋼筆的親密接觸,可以回到7年前,那時候在醫院,病例記錄還是手寫的,並且規定不可以用原子筆,只能用水性筆及鋼筆,從以前拿慣Hi-tech 0.3的我,一隻50臺幣的筆寫不了幾份病例就完蛋了。同事都在用鋼筆(大陸人從小就是拿鋼筆長大的),一罐碳素墨水也用不了幾塊錢,但是可以用N久,於是我就拿起我的彎尖鋼筆,開始我的鋼筆生活。
7年前的病例記錄
7年前的病例記錄